Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00116831
First received: June 30, 2005
Last updated: February 7, 2013
Last verified: July 2012
  Purpose

The purpose of this study is to test the safety and effectiveness of rosiglitazone against a sulfonylurea in reducing or slowing the development of atherosclerosis in the blood vessels of the heart.


Condition Intervention Phase
Non-Insulin-Dependent Diabetes Mellitus
Atherosclerosis
Cardiovascular Disease
Drug: Glipizide
Drug: rosiglitazone maleate
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone Versus Glipizide on the Progression of Atherosclerosis in Subjects With Type 2 Diabetes Mellitus and Cardiovascular Disease (APPROACH)

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Change From Baseline in Percent Atheroma Volume (PAV) to Month 18 [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    The primary efficacy endpoint was change in PAV (defined as total atheroma volume divided by total vessel volume x 100) within a 40 mm segment in non-intervened coronary arteries from Baseline to Month 18, based upon Intravascular Ultrasound (IVUS) assessment.

  • Model Adjusted Change From Baseline in Percent Atheroma Volume (PAV) to Month 18 [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    Model Adjusted Change (MAC) = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior Oral Anti-Hyperglycemic Diabetic Medications(s) (OAD).


Secondary Outcome Measures:
  • Change From Baseline in Atheroma, Vessel, and Lumen Volume to Month 18 [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18

  • Model Adjusted Change From Baseline in Atheroma Volume to Month 18 [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Model Adjusted Change (MAC) = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.

  • Model Adjusted Change From Baseline in Lumen Volume to Month 18 [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Model Adjusted Change (MAC) = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.

  • Model Adjusted Change From Baseline in Vessel Volume to Month 18 [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Model Adjusted Change (MAC) = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.

  • Change From Baseline in Atheroma, Vessel, and Lumen Area to Month 18 [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18

  • Model Adjusted Change From Baseline in Atheroma Area to Month 18 [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Model Adjusted Change (MAC) = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.

  • Model Adjusted Change From Baseline in Lumen Area to Month 18 [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Model Adjusted Change (MAC) = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.

  • Model Adjusted Change From Baseline in Vessel Area to Month 18 [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Model Adjusted Change (MAC) = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.

  • Change From Baseline in Normalized Atheroma Volume [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Normalized atheroma volume is defined as mean atheroma area x median segment length in cohort.

  • Model Adjusted Change From Baseline in Normalized Atheroma Volume [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Normalized atheroma volume is defined as mean atheroma area x median segment length in cohort. Model Adjusted Change = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.

  • Change in Atheroma Volume Within the 10 mm of the Non-intervened Vessel Segment With the Greatest Atheroma Volume at Baseline [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    IVUS-derived endpoints measured within the same 10 mm segment of non-intervened coronary arteries with the greatest degree of atheroma volume at Baseline, from Baseline to Month 18, including the nominal change in atheroma volume and atheroma area

  • Model Adjusted Change in Atheroma Volume Within the 10 mm of the Non-intervened Vessel Segment With the Greatest Atheroma Volume at Baseline [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    IVUS-derived endpoints measured within the same 10 mm segment of non-intervened coronary arteries with the greatest degree of atheroma volume at Baseline, from Baseline to Month 18, including the nominal change in atheroma volume and atheroma area. Model Adjusted Change = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.

  • Change in Atheroma Area Within the 10 mm of the Non-intervened Vessel Segment With the Greatest Atheroma Volume at Baseline [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    IVUS-derived endpoints measured within the same 10 mm segment of non-intervened coronary arteries with the greatest degree of atheroma volume at Baseline, from Baseline to Month 18, including the nominal change in atheroma volume and atheroma area

  • Model Adjusted Change in Atheroma Area Within the 10 mm of the Non-intervened Vessel Segment With the Greatest Atheroma Volume at Baseline [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    IVUS-derived endpoints measured within the same 10 mm segment of non-intervened coronary arteries with the greatest degree of atheroma volume at Baseline, from Baseline to Month 18, including the nominal change in atheroma volume and atheroma area. Model Adjusted Change = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.

  • Model Adjusted Change in Glycated Hemoglobin (HbA1c) From Baseline to Month 18 [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    From repeated measures analysis model: Change = Baseline + visit + sex + region + treatment + prior Oral Anti-Hyperglycemic Diabetic Medications(s) (OAD) + cardiac procedure + treatment x visit.

  • Model Adjusted Change in Fasting Plasma Glucose (FPG) From Baseline to Month 18 [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    From repeated measures analysis model: Change = Baseline + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  • Repeated Measures Analysis of Percent Change in hsCRP From Baseline to Month 18 [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    Changes in cardiovascular biomarkers from Baseline to Month 18, such as high sensitivity C-reactive protein (hsCRP) . Repeated measures analysis model: Log(value) - log(baseline) = log(baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  • Repeated Measures Analysis of Percent Change in MMP 9 From Baseline to Month 18 [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    Changes in cardiovascular biomarkers from Baseline to Month 18, such as matrix metalloproteinase-9 (MMP-9). Repeated measures analysis model: Log(value) - log(baseline) = log(baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  • Percent Change in Brain Natriuretic Peptide (BNP) From Baseline to Month 18 [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    It was measured as ratio to baseline as percentage change based on log-transformed data : 100 x (exp(Mean change on log scale) - 1)It was measured as ratio to baseline as percentage change based on log-transformed data : 100 x (exp(Mean change on log scale) - 1). Ratio to baseline as %change mean (%) was used as the estimation parameter for both groups.

  • Model Adjusted Percent Change in Brain Natriuretic Peptide (BNP) From Baseline to Month 18 [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    It was measured as ratio to baseline as percentage change based on log-transformed data : 100 x (exp(Mean change on log scale) - 1). Model Adjusted change based on ANCOVA: Log(value) - log(Baseline) = log(Baseline) + sex + region + treatment + prior OAD + cardiac procedure.

  • Percent Change From Baseline to Month 18 in Total Cholesterol (TC) [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  • Percent Change From Baseline to Month 18 in High Density Lipoprotein Cholesterol (HDL-c) [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  • Percent Change From Baseline to Month 18 in HDL-2 [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  • Percent Change From Baseline to Month 18 in HDL-3 [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  • Percent Change From Baseline to Month 18 in Low Density Lipoprotein Cholesterol (LDL-c) [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  • Percent Change From Baseline to Month 18 in Triglycerides (TG) [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  • Percent Change From Baseline to Month 18 in Free Fatty Acids (FFA) [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  • Percent Change From Baseline to Month 18 in Apoprotein B (apoB) [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  • Change From Baseline to Month 18 in LDL-c Peak Particle Density Measured by LDL Relative Flotation [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    From repeated measures analysis model: Change = baseline + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  • Change From Baseline to Month 18 in Total Cholesterol/HDL-c Ratio [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    From repeated measures analysis model: Change = baseline + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  • Change From Baseline to Month 18 in LDL-c/HDL-c Ratio [ Time Frame: Baseline to Month 18 ] [ Designated as safety issue: No ]
    From repeated measures analysis model: Change = baseline + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  • Number of Participants With the Indicated Treatment Emergent Major Cardiovascular Events (MACE) for All-cause Death, Non-fatal MI, Non-fatal Stroke, Coronary Revascularization, or Hospitalization for Recurrent Myocardial Ischemia (MACE Composite 1) [ Time Frame: Baseline to Month 21 ] [ Designated as safety issue: No ]
    This was 1 of 2 MACE composite endpoints and was a secondary efficacy endpoint.

  • Number of Participants With the Indicated Treatment Emergent Major Cardiovascular Events (MACE) for Cardiovascular Death, Nonfatal MI, or Nonfatal Stroke (MACE Composite 2) [ Time Frame: Baseline to Month 21 ] [ Designated as safety issue: No ]
    This was 1 of 2 MACE composite endpoints and was a secondary efficacy endpoint.

  • Number of Other Cardiovascular Events [ Time Frame: Baseline to Month 21 ] [ Designated as safety issue: No ]
    This was one of the secondary endpoints of the study.


Enrollment: 672
Study Start Date: January 2005
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Glipizide
oral anti-diabetic medication
Drug: Glipizide
oral anti-diabetic medication
Experimental: rosiglitazone maleate
oral anti-diabetic medication
Drug: rosiglitazone maleate
oral antidiabetic medication

  Eligibility

Ages Eligible for Study:   30 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Male or female between 30 to 80 years of age, inclusive.
  • Established diagnosis of T2DM (based on diagnostic criteria of the American Diabetes Association (ADA), WHO guidelines or local national guidelines).
  • Subjects who are undergoing coronary angiography for evaluation of suspected or previously diagnosed coronary artery disease or who are undergoing PCI.
  • Subjects' prior anti-hyperglycemic diabetic therapy:

Diet and exercise only (drug naïve), with HbA1c >7.0 and £ 10.0%. HbA1c > 6.5 and <= 8.5%.

  • Left ventricular ejection fraction (EF) ³ 40% as assessed by contrast ventriculography (or previously documented in medical notes within one month prior to index procedure by other methods e.g. echocardiography or nuclear study)
  • Female subjects must be postmenopausal (i.e., >6 months without menstrual period), surgically sterile, or using effective contraceptive measures (oral contraceptives, Norplant, Depo-Provera, an intra-uterine device (IUD), a diaphragm with spermicide or a condom with spermicide). Women of childbearing potential must use effective contraceptive measures for at least 1 month prior to visit 1a, and should continue to use the same contraceptive method during the study and for 30 days after discontinuing study medication.
  • Willingness and ability to give informed consent prior to entering the study and available to complete the study.

Exclusion Criteria:

  • Type 1 diabetes and/or history of diabetic ketoacidosis.
  • Exposure to a TZD or other PPAR-g agonist within the 6 months prior to screening visit.
  • Subjects treated with triple OAD therapy or high dose dual combination OAD therapy [1].
  • Subjects who have required chronic insulin use in the last 6 months (except during pregnancy or acute episodes such as hospitalization, trauma or infection).
  • ST segment elevation myocardial infarction in the last 30 days.
  • Subjects who have a history or are scheduled to receive coronary artery bypass graft surgery (CABG), valve repair or replacement, aneurysmectomy or planned major non-cardiac surgery during the study period.
  • Subjects who have severe cardiac valvular disease
  • Stroke or resuscitated in the past 6 months
  • History of congestive heart failure (NYHA class I - IV)
  • History of significant hypersensitivity or reaction (e.g., difficulty swallowing, difficulty breathing, tachycardia or skin reaction) to any TZD, SU, biguanide or insulin
  • Prior history of severe edema or edema requiring medical treatment.
  • Chronic disease requiring chronic or intermittent treatment with oral, intravenous, or injected corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible).
  • Recent history or suspicion of current drug abuse or alcohol abuse within the last 6 months.
  • Untreated hypo- or hyperthyroidism
  • A diagnosis of cancer (other than superficial squamous, basal cell skin cancer, or adequately treated cervical carcinoma in situ) in the past 3 years or current treatment for the active cancer.
  • Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgement of the Investigator, would preclude safe completion of the study.
  • Blood pressure: SBP >170 or DBP > 100 mmHg
  • Significant anemia (Hemoglobin < 11 g/dL for males and < 10 g/dL for females).
  • Significant renal disease manifested by serum creatinine (> 1.5mg/dL for males or > 1.4mg/dL for females), or where the use of metformin is contra-indicated.
  • Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST > 2.5 times upper limit of normal (ULN) or bilirubin >2x ULN).
  • History of myopathy or history of elevated creatine kinase (CK) > 3 times upper normal limit.
  • Use of an investigational drug within 30 days or 5 half-lives (whichever is the longer).
  • Women who are lactating, pregnant or planning to become pregnant during the course of the study.
  • Unwillingness or inability to comply with the procedures described in this protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00116831

  Hide Study Locations
Locations
United States, Alabama
GSK Investigational Site
Birmingham, Alabama, United States, 35235
United States, Arizona
GSK Investigational Site
Scottsdale, Arizona, United States, 85251
GSK Investigational Site
Tucson, Arizona, United States, 85745
United States, California
GSK Investigational Site
Burbank, California, United States, 91505
GSK Investigational Site
Huntington Beach, California, United States, 92648
GSK Investigational Site
Los Angeles, California, United States, 90017
GSK Investigational Site
Mission Viejo, California, United States, 92691
GSK Investigational Site
Sacramento, California, United States, 95825
GSK Investigational Site
Sacramento, California, United States, 95817
GSK Investigational Site
Torrance, California, United States, 90503
GSK Investigational Site
Torrance, California, United States, 90509
United States, Colorado
GSK Investigational Site
Denver, Colorado, United States, 80220
GSK Investigational Site
Englewood, Colorado, United States, 80113
United States, District of Columbia
GSK Investigational Site
Washington, District of Columbia, United States, 20010
United States, Florida
GSK Investigational Site
Melbourne, Florida, United States, 32901
GSK Investigational Site
Tampa, Florida, United States, 33609
United States, Georgia
GSK Investigational Site
Atlanta, Georgia, United States, 30309
United States, Illinois
GSK Investigational Site
Peoria, Illinois, United States, 61615
GSK Investigational Site
Springfield, Illinois, United States, 62702
United States, Indiana
GSK Investigational Site
Indianapolis, Indiana, United States, 46260
United States, Maryland
GSK Investigational Site
Baltimore, Maryland, United States, 21287
GSK Investigational Site
Columbia, Maryland, United States, 21044
United States, Massachusetts
GSK Investigational Site
Springfield, Massachusetts, United States, 01199
United States, Missouri
GSK Investigational Site
Springfield, Missouri, United States, 65807
United States, New Jersey
GSK Investigational Site
New Brunswick, New Jersey, United States, 08903
United States, New York
GSK Investigational Site
Albany, New York, United States, 12208
GSK Investigational Site
New York, New York, United States, 10032
United States, North Carolina
GSK Investigational Site
Winston-Salem, North Carolina, United States, 27103
GSK Investigational Site
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
GSK Investigational Site
Canton, Ohio, United States, 44708
United States, Pennsylvania
GSK Investigational Site
Beaver, Pennsylvania, United States, 15009
GSK Investigational Site
Camp Hill, Pennsylvania, United States, 17011
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19141
United States, Tennessee
GSK Investigational Site
Jackson, Tennessee, United States, 38301
United States, Texas
GSK Investigational Site
Corpus Christi, Texas, United States, 78404
GSK Investigational Site
San Antonio, Texas, United States, 78207
GSK Investigational Site
San Antonio, Texas, United States, 78229
United States, Washington
GSK Investigational Site
Bellevue, Washington, United States, 98004
United States, Wisconsin
GSK Investigational Site
Milwaukee, Wisconsin, United States, 53215
Argentina
GSK Investigational Site
Capital Federal, Buenos Aires, Argentina, C1155ADP
GSK Investigational Site
Capital Federal, Buenos Aires, Argentina, C1437JCP
GSK Investigational Site
Capital Federal, Buenos Aires, Argentina, 1181
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, B1704ETD
GSK Investigational Site
Munro, Buenos Aires, Argentina, 1605
GSK Investigational Site
San Justo, Buenos Aires, Argentina, B7118XAB
GSK Investigational Site
San Martín, Buenos Aires, Argentina, 1650
GSK Investigational Site
Córdoba, Córdova, Argentina, 5000
GSK Investigational Site
Buenos Aires, Argentina, 1428
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Argentina, 1416
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Argentina, 1221
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Argentina, C1416DRW
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Argentina, 1405
GSK Investigational Site
Cordoba, Argentina, 5000
GSK Investigational Site
Moron-Provincia de Buenos Aires, Argentina, 1709
Brazil
GSK Investigational Site
Ribeirão Preto, São Paulo, Brazil, 14048-900
GSK Investigational Site
São Paulo, Brazil, 04012-909
GSK Investigational Site
São Paulo, Brazil, 05403-000
GSK Investigational Site
São Paulo, Brazil, 05651-901
Canada, Ontario
GSK Investigational Site
Hamilton, Ontario, Canada, L8L 2X2
GSK Investigational Site
London, Ontario, Canada, N6A 4V2
GSK Investigational Site
Toronto, Ontario, Canada, M4N 3M5
GSK Investigational Site
Toronto, Ontario, Canada, M5B 1W8
Canada, Quebec
GSK Investigational Site
Montreal, Quebec, Canada, H1T 1C8
Czech Republic
GSK Investigational Site
Hradec Kralove, Czech Republic, 500 05
France
GSK Investigational Site
Corbeil Essonnes Cedex, France, 91106
GSK Investigational Site
Le Plessis Robinson, France, 92350
GSK Investigational Site
Marseille, France, 13005
GSK Investigational Site
Rennes Cedex, France, 35033
Germany
GSK Investigational Site
Heidelberg, Baden-Wuerttemberg, Germany, 69120
GSK Investigational Site
Heidelberg, Baden-Wuerttemberg, Germany, 69126
GSK Investigational Site
Mannheim, Baden-Wuerttemberg, Germany, 68161
GSK Investigational Site
Coburg, Bayern, Germany, 96450
GSK Investigational Site
Kronach, Bayern, Germany, 96317
GSK Investigational Site
Kulmbach, Bayern, Germany, 95326
GSK Investigational Site
Lichtenfels, Bayern, Germany, 96215
GSK Investigational Site
Hirschhorn, Hessen, Germany, 69434
GSK Investigational Site
Lampertheim, Hessen, Germany, 68623
GSK Investigational Site
Bochum, Nordrhein-Westfalen, Germany, 44789
GSK Investigational Site
Dinslaken, Nordrhein-Westfalen, Germany, 46537
GSK Investigational Site
Dormagen, Nordrhein-Westfalen, Germany, 41539
GSK Investigational Site
Dortmund, Nordrhein-Westfalen, Germany, 44339
GSK Investigational Site
Dortmund, Nordrhein-Westfalen, Germany, 44137
GSK Investigational Site
Dortmund, Nordrhein-Westfalen, Germany, 44328
GSK Investigational Site
Duesseldorf, Nordrhein-Westfalen, Germany, 40454
GSK Investigational Site
Duisburg, Nordrhein-Westfalen, Germany, 47119
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45359
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45136
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45329
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45309
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45122
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45355
GSK Investigational Site
Gelsenkirchen, Nordrhein-Westfalen, Germany, 45881
GSK Investigational Site
Herne, Nordrhein-Westfalen, Germany, 44623
GSK Investigational Site
Herne, Nordrhein-Westfalen, Germany, 44653
GSK Investigational Site
Leverkusen, Nordrhein-Westfalen, Germany, 51377
GSK Investigational Site
Luenen, Nordrhein-Westfalen, Germany, 44534
GSK Investigational Site
Marl, Nordrhein-Westfalen, Germany, 45772
GSK Investigational Site
Oberhausen, Nordrhein-Westfalen, Germany, 46049
GSK Investigational Site
Ludwigshafen, Rheinland-Pfalz, Germany, 67063
GSK Investigational Site
Rhaunen, Rheinland-Pfalz, Germany, 55624
GSK Investigational Site
Speyer, Rheinland-Pfalz, Germany, 67346
GSK Investigational Site
Trier, Rheinland-Pfalz, Germany, 54292
GSK Investigational Site
Trier, Rheinland-Pfalz, Germany, 54296
GSK Investigational Site
Friedrichsthal, Saarland, Germany, 66299
GSK Investigational Site
Saarlouis, Saarland, Germany, 66740
GSK Investigational Site
Sr. Ingbert, Saarland, Germany, 66386
Greece
GSK Investigational Site
Athens, Greece, 155 62
GSK Investigational Site
Athens, Greece, 176 74
GSK Investigational Site
Athens, Greece, 115 27
GSK Investigational Site
Athens, Greece, 115 26
Hong Kong
GSK Investigational Site
Causeway Bay, Hong Kong
GSK Investigational Site
Kowloon, Hong Kong
GSK Investigational Site
Kwun Tong, Hong Kong
GSK Investigational Site
Pokfulam, Hong Kong
GSK Investigational Site
Shatin, Hong Kong
India
GSK Investigational Site
Mumbai, India, 400005
GSK Investigational Site
New Delhi, India, 110017
Italy
GSK Investigational Site
Udine, Friuli-Venezia-Giulia, Italy, 33100
GSK Investigational Site
Rozzano (Mi), Lombardia, Italy, 20089
Korea, Republic of
GSK Investigational Site
Seoul, Korea, Republic of, 110-744
GSK Investigational Site
Seoul, Korea, Republic of, 120-752
GSK Investigational Site
Seoul, Korea, Republic of, 138-736
GSK Investigational Site
Suwon-Si, Korea, Republic of, 443-721
Latvia
GSK Investigational Site
Riga, Latvia, LV1002
Mexico
GSK Investigational Site
Guadalajara, Jalisco, Mexico, 44340
GSK Investigational Site
Monterrey, Nuevo León, Mexico, 64060
Netherlands
GSK Investigational Site
Breda, Netherlands, 4818 CK
GSK Investigational Site
Eindhoven, Netherlands, 5623 EJ
GSK Investigational Site
Enschede, Netherlands, 7511JX
GSK Investigational Site
Nieuwegein, Netherlands, 3435 CM
GSK Investigational Site
Rotterdam, Netherlands, 3015 GD
GSK Investigational Site
Rotterdam, Netherlands, 3075 EA
GSK Investigational Site
Zwolle, Netherlands, 8011 JW
Poland
GSK Investigational Site
Bialystok, Poland, 15-276
GSK Investigational Site
Kalisz, Poland, 62-800
GSK Investigational Site
Katowice, Poland, 40-635
GSK Investigational Site
Poznan, Poland, 60-355
GSK Investigational Site
Warszawa, Poland, 04-628
Russian Federation
GSK Investigational Site
Moscow, Russian Federation, 121552
GSK Investigational Site
Moscow, Russian Federation, 105 229
GSK Investigational Site
Moscow, Russian Federation, 123182
Spain
GSK Investigational Site
Alicante, Spain, 03010
GSK Investigational Site
Badalona, Spain, 08916
GSK Investigational Site
Barcelona, Spain, 08097
GSK Investigational Site
Barcelona, Spain, 08035
GSK Investigational Site
Barcelona, Spain, 08036
GSK Investigational Site
Madrid, Spain, 28035
GSK Investigational Site
Malaga, Spain, 29010
GSK Investigational Site
Marid, Spain, 28040
GSK Investigational Site
Murcia, Spain, 30120
GSK Investigational Site
Oviedo, Spain, 33006
GSK Investigational Site
San Juan/Alicante, Spain, 03550
Sweden
GSK Investigational Site
Göteborg, Sweden, SE-413 45
GSK Investigational Site
Stockholm, Sweden, SE-171 76
Thailand
GSK Investigational Site
Bangkok, Thailand, 10330
GSK Investigational Site
Chiang Mai, Thailand, 50200
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00116831     History of Changes
Other Study ID Numbers: AVD100521
Study First Received: June 30, 2005
Results First Received: August 7, 2009
Last Updated: February 7, 2013
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
Canada: Health Canada
United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
atheroma
IVUS
Intravascular ultrasound
atherosclerosis

Additional relevant MeSH terms:
Arteriosclerosis
Atherosclerosis
Cardiovascular Diseases
Diabetes Mellitus
Diabetes Mellitus, Type 2
Arterial Occlusive Diseases
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Vascular Diseases
Glipizide
Rosiglitazone
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 21, 2014